SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Decline in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 58,800 shares, a decline of 26.3% from the October 15th total of 79,800 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 64,100 shares, the short-interest ratio is presently 0.9 days.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SABS shares. Oppenheimer restated an “outperform” rating and set a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Craig Hallum started coverage on SAB Biotherapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.40.

SAB Biotherapeutics Stock Down 16.2 %

SAB Biotherapeutics stock traded down $0.60 during midday trading on Friday, reaching $3.10. The company’s stock had a trading volume of 84,880 shares, compared to its average volume of 30,583. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $2.95 and its 200-day simple moving average is $2.98. SAB Biotherapeutics has a 52-week low of $2.16 and a 52-week high of $9.72.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, equities analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics at the end of the most recent quarter. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.